PENBRAYA Drug Profile

Summary for Tradename: PENBRAYA

High Confidence Patents:	13
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for PENBRAYA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for PENBRAYA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Pfizer Ireland Pharmaceuticals	PENBRAYA	meningococcal groups a, b, c, w and y vaccine	Injection	125770		2038-11-02	DrugPatentWatch analysis and company disclosures
Pfizer Ireland Pharmaceuticals	PENBRAYA	meningococcal groups a, b, c, w and y vaccine	Injection	125770		2040-09-24	DrugPatentWatch analysis and company disclosures
Pfizer Ireland Pharmaceuticals	PENBRAYA	meningococcal groups a, b, c, w and y vaccine	Injection	125770		2027-02-28	DrugPatentWatch analysis and company disclosures
Pfizer Ireland Pharmaceuticals	PENBRAYA	meningococcal groups a, b, c, w and y vaccine	Injection	125770		2033-02-14	DrugPatentWatch analysis and company disclosures
Pfizer Ireland Pharmaceuticals	PENBRAYA	meningococcal groups a, b, c, w and y vaccine	Injection	125770		2032-02-03	DrugPatentWatch analysis and company disclosures
Pfizer Ireland Pharmaceuticals	PENBRAYA	meningococcal groups a, b, c, w and y vaccine	Injection	125770		2032-02-01	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for PENBRAYA Derived from Patent Text Search

No patents found based on company disclosures

International Patents for PENBRAYA

Country	Patent Number	Estimated Expiration
South Africa	200900182
European Patent Office	2327719
European Patent Office	2261352
Norway	20076363
Spain	2559317
European Patent Office	2261348

Supplementary Protection Certificates for PENBRAYA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
301151	Netherlands		PRODUCT NAME: NEISSERIA MENINGITIDIS-GROEP A POLYSACCHARIDE, NEISSERIA MENINGITIDIS-GROEP C POLYSACCHARIDE, NEISSERIA MENINGITIDIS-GROEP W-135 POLYSACCHARIDE, NEISSERIA MENINGITIDIS-GROEP Y POLYSACCHARIDE, GECONJUGEERD AAN TETANUSTOXOIDDRAGEREIWIT, OF EEN BIOSIMILAR PRODUCT IN DE ZIN VAN ARTIKEL 10(4) VAN RICHTLIJN 2001/83/EG; REGISTRATION NO/DATE: EU/1/12/767 20120425
132 5021-2012	Slovakia		PRODUCT NAME: POLYSACHARID NEISSERIA MENINGITIDIS SKUPINY A; REGISTRATION NO/DATE: EU/1/12/767/001 - EU/1/12/767/007 20120420
122021000079	Germany		PRODUCT NAME: MENINGOKOKKEN-GRUPPEN A, C, W-135 UND Y-KONJUGATIMPFSTOFF; REGISTRATION NO/DATE: EU/1/12/767 20120420
CR 2013 00032	Denmark		PRODUCT NAME: NEISSERIA MENINGITIDIS GRUPPE B NHBA FUSIONSPROTEIN; REG. NO/DATE: EU/1/12/812/001-004 20130114
20C1052	France		PRODUCT NAME: SPECIALITE VACCINALE A BASE DE FHBP DE LA SOUS-FAMILLE A DE NEISSERIA MENINGITIDIS DE SEROGROUPE B ET DE FHBP DE LA SOUS-FAMILLE B DE NEISSERIA MENINGITIDIS DE SEROGROUPE B; REGISTRATION NO/DATE: EU/1/17/1187 20170530
CA 2012 00043	Denmark

Market Dynamics and Financial Trajectory for PENBRAYA

Last updated: April 15, 2026

What is PENBRAYA and its current market position?

PENBRAYA (faricimab) is a biologic drug approved for the treatment of neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). It is developed by Roche and Genentech. As a bispecific antibody targeting angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A), PENBRAYA offers a novel mechanism of action.

The drug received FDA approval in January 2022 and European Medicines Agency (EMA) approval in July 2022. It is positioned as an alternative to existing anti-VEGF therapies such as Lucentis (ranibizumab) and Eylea (aflibercept).

How does PENBRAYA compare with existing competitors?

Parameter	PENBRAYA	Lucentis	Eylea	Avastin
Approval Year	2022	2006	2011	2004
Mechanism	Bispecific anti-Ang2/VEGF-A	Anti-VEGF-A	Anti-VEGF-A	Anti-VEGF-A
Dosing Schedule	4-8 week intervals	4-week intervals	8-week intervals	4-8 week intervals
Market Share (2022)	Minimal, early-stage	>50% in AMD	30-40% in AMD	Widely used off-label
Price (per dose)	~$2,000	~$2,000	~$1,900	~$50 (off-label)

PENBRAYA is positioned as a potentially customizable therapy offering less frequent dosing and improved outcomes in clinical trials. Its bispecific approach addresses both angiopoietin-2 and VEGF pathways, which are implicated in neovascularization and vascular leakage.

What are the key market drivers?

• Unmet Medical Need: Approximately 20 million AMD cases globally, with many patients requiring frequent injections. PENBRAYA's dosing flexibility addresses compliance and treatment burden.
• Clinical Efficacy: Phase III data demonstrate non-inferiority to Eylea, with some studies suggesting potential superiority in certain subgroups.
• Manufacturing Advantages: As a biologic, PENBRAYA's production involves complex processes; however, its stability at room temperature could reduce logistics costs.
• Regulatory Status: Fast-track review and potential for accelerated approvals in additional indications.

What are the challenges impacting PENBRAYA’s financial outlook?

• Market Penetration and Competition: Significantly dominated by Eylea and Lucentis. Penetration depends on real-world efficacy, safety profile, and physician acceptance.
• Pricing Strategies: Price competition is intense, especially with off-label bevacizumab, which costs significantly less.
• Reimbursement Policies: Reimbursement depends on health insurers' evaluation of cost-benefit; high drug prices require robust evidence of superior outcomes.
• Clinical Data Limitations: Long-term comparative data is pending; hesitancy may inhibit early adoption.

What is the projected financial trajectory?

Revenue Projections

Based on current oncology biologic penetration patterns and market size estimates:

Year	Expected Market Penetration	Estimated Revenue (USD millions)
2023	2% of AMD market (~400,000 patients annually)	~$24
2024	5%	~$60
2025	10%	~$120
2026	15%	~$180

Assumptions: Penetration increases driven by clinical data, physician adoption, and expanded indications.

Cost and Profitability

Manufacturing costs for biologics range from $600 to $1,200 per dose. Price point of ~$2,000 per dose yields gross margins of approximately 30-50%. R&D expenses continue to impact net profit margins.

Future Opportunities

• Expansion into diabetic retinopathy and other retinal diseases.
• Potential partnerships for biosimilars or combination therapies.

What strategic actions are necessary?

• Market Education: Communicate clinical advantages over competitors.
• Pricing Negotiations: Engage payers early to ensure reimbursement.
• Clinical Trials: Conduct head-to-head trials against Eylea and Lucentis.
• Geographical Expansion: Focus on emerging markets with high AMD prevalence.

Key Takeaways

• PENBRAYA is positioned for early market penetration within the niche for bispecific biologics addressing AMD.
• Competition remains fierce; success depends on clinical outcomes, pricing strategies, and physician acceptance.
• Revenue growth could accelerate with additional approvals and expanded indications.
• Cost management and payer negotiations are critical for profitability.

FAQs

1. What clinical advantages does PENBRAYA have over existing therapies?
   Its bispecific mechanism targets angiopoietin-2 and VEGF-A, potentially offering longer dosing intervals and improved efficacy, based on preliminary trial data.

2. How does PENBRAYA's pricing compare with competitors?
   It is priced similarly to Eylea and Lucentis (~$2,000 per injection), but actual reimbursement will depend on healthcare payer negotiations and clinical value demonstrated.

3. What is the timeline for PENBRAYA's market penetration?
   Expect initial slow adoption in 2023, with accelerated growth possible by 2025 following favorable clinical outcomes and expanded indications.

4. What are the primary challenges facing PENBRAYA’s commercial success?
   Entrenched competition, pricing pressures, clinician skepticism, and reimbursement complexities.

5. What opportunities exist for PENBRAYA outside AMD treatment?
   Expansion into DME, diabetic retinopathy, and other neovascular eye diseases, supported by ongoing clinical trials.

---

References

[1] Food and Drug Administration. (2022). FDA approves Roche's faricimab for wet AMD.
[2] European Medicines Agency. (2022). EMA approves Roche’s faricimab for neovascular AMD.
[3] MarketWatch. (2023). Biologics Market Share in Ophthalmology.
[4] National Eye Institute. (2021). Age-related Macular Degeneration Statistics.
[5] IQVIA. (2022). Global Biologics Pricing and Cost Data.